Mexico - Delayed Quote MXN

NeoGenomics, Inc. (NEO.MX)

200.00

0.00

(0.00%)

As of February 28 at 11:35:49 AM CST. Market Open.

NeoGenomics price target lowered to $10 from $17 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on NeoGenomics (NEO) to $10 from $17 and keeps an Equal Weight rating on the shares. The company’s Q1 miss was primarily driven by lower non-clinical revenue and lower than expected average unit price, says the analyst, who sees “more questions than answers” following the company’s quarterly report. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analys

TipRanks 4 days ago

NEO
NeoGenomics Pays Off 1.25% Convertible Senior Notes

FORT MYERS, Fla., May 01, 2025--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.

Business Wire 4 days ago

NEO
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary ultra-high throughput next-generation sequencing (NGS) platform, today announced a collaboration to use Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance NeoGenomics' ability to offer innovative clinical tests. NeoGenomics has purchased a UG 100 sequencer that will be installed in its innovation cent

PR Newswire 6 days ago

NEO
NeoGenomics Reports First Quarter 2025 Results

FORT MYERS, Fla., April 29, 2025--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.

Business Wire 6 days ago

NEO
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

FORT MYERS, Fla., April 22, 2025--NeoGenomics announced analytical validation of its PanTracer LBx™ assay, to be presented with five other abstracts at the AACR Annual Meeting 2025.

Business Wire 13 days ago

NEO
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

FORT MYERS, Fla., April 08, 2025--NeoGenomics will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025.

Business Wire 27 days ago

NEO
NeoGenomics Completes Acquisition of Pathline

FORT MYERS, Fla., April 07, 2025--NeoGenomics has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.

Business Wire 28 days ago

NEO
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

FT. MYERS, Fla., April 01, 2025--NeoGenomics announced that Tony Zook has officially assumed the role of Chief Executive Officer.

Business Wire last month

NEO
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

FT. MYERS, Fla., March 18, 2025--NeoGenomics has promoted Warren Stone, the Company’s current Chief Commercial Officer, to President & Chief Operating Officer, effective April 1, 2025

Business Wire last month

NEO
3 Small-Cap Stocks in Hot Water

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

StockStory last month

AMN

NEO

MATW
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

FT. MYERS, Fla., March 10, 2025--NeoGenomics announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.

Business Wire last month

NEO
NeoGenomics to Participate in Upcoming Investor Conferences

FT. MYERS, Fla., February 24, 2025--NeoGenomics will participate in several upcoming investor conferences.

Business Wire 2 months ago

NEO
NeoGenomics Full Year 2024 Earnings: EPS Beats Expectations

NeoGenomics ( NASDAQ:NEO ) Full Year 2024 Results Key Financial Results Revenue: US$660.6m (up 12% from FY 2023). Net...

Simply Wall St. 2 months ago

NEO
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

FORT MYERS, Fla., February 18, 2025--NeoGenomics announced its fourth-quarter and full year results for the period ended December 31, 2024.

Business Wire 2 months ago

NEO
PacBio Announces Appointment of Chris Smith to Board of Directors

PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down.MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services co

GlobeNewswire 3 months ago

PACB

NEO
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

FORT MYERS, Fla., January 29, 2025--NeoGenomics will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Feb. 18, 2025.

Business Wire 3 months ago

NEO
Strong week for NeoGenomics (NASDAQ:NEO) shareholders doesn't alleviate pain of five-year loss

While not a mind-blowing move, it is good to see that the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has gained 10...

Simply Wall St. 3 months ago

NEO
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance

NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a recent selloff.

Investor's Business Daily 3 months ago

NEO
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

FT. MYERS, Fla., January 15, 2025--NeoGenomics today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.

Business Wire 3 months ago

NEO
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuumSEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (N

GlobeNewswire 3 months ago

ADPT

NEO

Performance Overview

Return	NEO.MX	S&P 500 (^GSPC)
YTD	-41.18%	-3.37%
1-Year	+0.76%	+10.83%
3-Year	+0.76%	+37.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NeoGenomics, Inc. (NEO.MX)

NeoGenomics price target lowered to $10 from $17 at Morgan Stanley

NeoGenomics Pays Off 1.25% Convertible Senior Notes

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

NeoGenomics Reports First Quarter 2025 Results

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

NeoGenomics Completes Acquisition of Pathline

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

3 Small-Cap Stocks in Hot Water

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics Full Year 2024 Earnings: EPS Beats Expectations

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

PacBio Announces Appointment of Chris Smith to Board of Directors

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

Strong week for NeoGenomics (NASDAQ:NEO) shareholders doesn't alleviate pain of five-year loss

NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Performance Overview